Traditional therapeutic strategies for coronary artery disease (CAD) primarily focus on arterial perfusion, largely overlooking the critical role of the cardiac lymphatic system in maintaining myocardial fluid, lipid, and immune homeostasis. The vascular endothelial growth factor C (VEGF-C) and VEGF-D/VEGF receptor-3 (VEGFR3) signaling axes are the primary drivers of lymphangiogenesis. However, recent clinical and mechanistic insights suggest that these two homologous ligands exert highly distinct and divergent pathophysiological roles under ischemic stress. This review synthesizes the current clinical, epidemiological, and preclinical evidence evaluating the distinct temporal and spatial dynamics of the VEGF-C/D axis. Large-scale clinical cohorts have revealed a striking prognostic divergence: while elevated circulating VEGF-D levels independently predict incident heart failure, atrial fibrillation, and mortality, low serum VEGF-C levels independently predict mortality. Mechanistically, adventitial lymphatics actively govern scavenger receptor class B type I (SR-BI)-dependent reverse cholesterol transport and macrophage trafficking. Preclinical large animal validation and phase 1/2 clinical trials (such as KAT301 and ReGenHeart) have demonstrated that timely, localized pro-lymphangiogenic interventions—leveraging modified mRNA, lipid nanoparticles, or sequential growth factor delivery kinetics—effectively resolve myocardial edema, suppress adverse remodeling, and improve the myocardial perfusion reserve. In conclusion, VEGF-C and VEGF-D represent a complex molecular dualism in CAD. Transitioning from non-specific growth factor overproduction to cell-specific, sequentially timed lymphatic therapeutics is a new frontier in halting the progression of adverse ventricular remodeling and chronic heart failure.
Dyslipidemia is a major risk factor for atherosclerosis, and high low-density lipoprotein (LDL) cholesterol is closely associated with the onset of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease. Numerous large-scale clinical trials have demonstrated that LDL cholesterol-lowering therapy, primarily involving statins, reduces not only coronary events, but also stroke, and has been established as a cornerstone of cardiovascular prevention. However, ischemic stroke is a group of diseases comprising different pathologies, such as atherothrombotic stroke, cardioembolic stroke, and small-vessel disease; the involvement of dyslipidemia and the efficacy of lipid-lowering therapy vary significantly depending on the subtype. Therefore, the evidence established for coronary artery disease cannot necessarily be applied directly to stroke management, and establishing lipid management strategies tailored to each subtype has become a critical challenge in stroke management. Furthermore, in recent years, in addition to LDL cholesterol-lowering therapy, treatments targeting hypertriglyceridemia, lipoprotein(a) [Lp(a)], and residual inflammatory risk have advanced, and the development of new therapeutic agents—such as PCSK9 inhibitors, selective PPARα modulators, and ATP citrate lyase inhibitors—is progressing, thus raising expectations for their application in stroke prevention. This article provides an overview of domestic and international guidelines for dyslipidemia and summarizes the association between dyslipidemia and ischemic stroke from the perspectives of pathophysiology, pathological findings, and imaging and blood biomarker. In addition, it outlines the latest evidence from large-scale clinical trials, new lipid-lowering therapies, acute-phase lipid management, and interventions targeting residual risk, and discusses the current status and future prospects of lipid management tailored to specific stroke subtypes.
Aim: Children with elevated low-density lipoprotein cholesterol (LDL-C) levels, suspected familial hypercholesterolemia (FH), and elevated lipoprotein(a) (Lp(a)) levels are considered to have a particularly high lifetime risk of atherosclerotic cardiovascular disease. Nevertheless, the distribution of Lp(a) levels among children with elevated LDL-C levels remains unclear. This study aimed to clarify the distribution of Lp(a) levels and their association with pathogenic FH variants in children with elevated LDL-C levels.
Methods: A total of 97 children with LDL-C levels ≥ 140 mg/dL suspected of having FH who underwent genetic testing at Kagawa University Hospital between January 2018 and May 2025 were analyzed. Lp(a) levels were measured using the Lp(a) Latex “DAIICHI” assay and converted from mass units (mg/dL) to molar units (nmol/L) using the calibration-based conversion formula. Clinical and lipid parameters were compared according to Lp(a) levels (≥ 105 vs. <105 nmol/L) and the presence of pathogenic FH variants.
Results: Lp(a) levels exhibited a right-skewed distribution, with a median of 57.6 nmol/L (15.9 mg/dL) and an interquartile range of 24.0–93.4 nmol/L (7.0–25.4 mg/dL), and 21.6% of children had levels ≥ 105 nmol/L. Pathogenic FH variants were identified in 44 children. No significant differences were observed in either clinical or lipid parameters according to Lp(a) levels (≥ 105 vs. <105 nmol/L) or the presence of pathogenic FH variants (P = 0.672).
Conclusion: Regardless of the presence of pathogenic FH variants, approximately 20% of the children had Lp(a) levels ≥ 105 nmol/L. These findings emphasize the importance of early lipid management and suggest that Lp(a) measurement may contribute to future cardiovascular risk stratification.
Aim: Chronic limb-threatening ischemia (CLTI), the most advanced stage of lower-extremity artery disease, is associated with high mortality and major amputation rates, even after revascularization. Thus, identifying patients with CLTI at a particularly high risk of poor outcomes is crucial for shared decision making. Recently, the C-reactive protein-to-albumin ratio (CAR) has emerged as a novel composite biomarker that reflects both the inflammatory and nutritional status. Nonetheless, the prognostic significance of CAR in patients with CLTI undergoing endovascular therapy (EVT) remains unclear.
Methods: Of 159 patients who underwent EVT for the first time between April 2010 and December 2023, 79 were included in this study. The patients were categorized into two groups using a CAR value of 0.17: the high-CAR group (CAR ≥ 0.17) and the low-CAR group (CAR <0.17). The primary endpoint was 1-year amputation-free survival (AFS) after EVT.
Results: The median follow-up period was 23 months (95% confidence interval [CI], 11–34). During the follow-up period, 56 patients (71%) died and 11 (14%) underwent major amputation. AFS was significantly reduced in the high-CAR group (log-rank P<0.01). The CAR (hazard ratio: 1.43 per one-unit increase, 95% CI: 1.20–1.70, P<0.01) was an independent predictor of reduced AFS following EVT.
Conclusions: elevated preprocedural CAR was independently associated with reduced AFS after EVT in patients with CLTI. The CAR may serve as a valuable tool for evaluating patients with CLTI before EVT.
Aim: Atrial cardiomyopathy (AC) is associated with cardiovascular events, but the benefit of anticoagulation in embolic stroke of an undetermined source (ESUS) remains unclear. We aimed to prospectively evaluate the prognostic value of AC in patients with ESUS.
Methods: We prospectively enrolled patients with ESUS who were hospitalized within 7 days of onset (January 2019 - December 2021). AC was defined as an N-terminal pro-B-type natriuretic peptide level >250 pg/ml, P-wave terminal force in lead V1 >5000 µV·ms, or enlarged left atrial diameter. Ischemic stroke/transient ischemic attack (TIA) recurrence was evaluated using Fine–Gray sub-distribution hazard models with death as a competing event. Cox proportional hazards models were used for supportive analyses and all-cause mortality.
Results: Among the 345 patients (mean age 59.22±13.19 years; 69.0% men), 42.0% met the criteria for AC. During a median follow-up of 18.1 months, 36 patients experienced ischemic stroke, 2 had TIA, and 18 died. AC was strongly associated with ischemic stroke/TIA recurrence in competing risk analyses (adjusted subdistribution hazard ratio [aSHR] 3.36, 95% CI 1.65–6.86; P<0.001). For all-cause mortality, AC was associated with a higher risk after adjusting for age and sex (adjusted hazard ratio 3.80, 95% CI 1.19–12.08; P = 0.024). Adding AC to conventional risk models significantly improved the NRI (ischemic stroke/transient ischemic attack: 72.45%, P<0.001; mortality: 66.16%, P = 0.002) and IDI (4.52%, P<0.001; 3.89%, P = 0.041).
Conclusions: AC independently predicts recurrent ischemic stroke/TIA in ESUS and improves risk stratification, while its association with mortality requires cautious interpretation due to limited events.
Aims: The quantitative flow ratio (QFR)-derived pullback pressure gradient (PPG) characterizes the pathophysiological patterns of coronary atherosclerosis. This study investigated the plaque morphologies associated with these disease patterns.
Methods: This study used the institutional QFR-PPG database registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000056097). Patients who underwent elective stenting with pre-procedural optical coherence tomography and near-infrared spectroscopy intravascular ultrasound were included. Offline QFR and QFR-PPG analyses were performed, and the lesions were stratified into tertiles.
Results: A total of 168 de novo lesions were analyzed in this study. The QFR tertiles were defined as severe (<0.61), moderate (0.61–0.71), and mild (>0.71); the QFR-PPG tertiles were defined as diffuse (<0.66), intermediate (0.66–0.79), and focal (>0.79). The Severe QFR tertiles exhibited a smaller minimum lumen area (MLA) and higher frequencies of thin-cap fibroatheroma (TCFA) and layered plaque. In contrast, across the QFR-PPG tertiles, MLA and TCFA frequencies were similar, whereas the diffuse group exhibited more layered plaques and larger calcium angles. The maximum lipid-core burden index did not vary across the QFR-PPG tertiles. A multivariable analysis identified MLA and TCFA as independent predictors of QFR, while layered plaque and calcium angle independently predicted QFR-PPG. However, the lipidic features were not independent predictors of QFR.
Conclusion: Multimodal intracoronary imaging demonstrated that QFR reflects luminal narrowing and the features of vulnerable plaques. Conversely, QFR-PPG reflects disease diffuseness, characterized by layered plaques and calcium burden rather than lipid-rich features.
Aim: Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). Recommended lipid-lowering therapy (LLT) includes both oral (e.g., statins) and injectable agents. However, patient awareness of LDL-C management and adherence to it remain uncertain.
Methods: This cross-sectional study surveyed 415 Japanese patients with ASCVD using a web-based platform. The participants reported their understanding of LDL-C target values and the effects of LLT. Medication adherence was evaluated using the Extent of Nonadherence scale, and a binomial logistic regression analysis was performed to identify the factors associated with nonadherence.
Results: Approximately 58.1%–60.2% of the participants reported confidence in knowing their correct lipid target values and managing dyslipidemia appropriately. However, only 22.2% reported LDL-C targets of <50 or <70 mg/dL, and 43.4% believed their targets to be <50, <70, or <100 mg/dL. In contrast, 56.7% either reported LDL-C targets of <120, <140, or <160 mg/dL or did not know their targets. Regarding LLT, 65.8% were unaware that extreme lowering of LDL-C levels with LLT had no disadvantages, and 74.2% were unaware that injectable LLTs were available. Overall, 39.0% of the participants were nonadherent. Higher out-of-pocket costs (≥ 3,001 yen; adjusted odds ratio [OR]: 1.83, p = 0.024) and experience with self-injections (adjusted odds ratio: 2.34, p = 0.027) were significantly associated with nonadherence.
Conclusions: Our findings highlight a considerable gap in patient knowledge and adherence to dyslipidemia management strategies. Interventions that promote patient education and shared decision-making are essential for improving adherence and achieving optimal LDL-C targets.
Aims: Ischemic stroke (IS) is a leading global cause of death and disability. The lactate-to-hematocrit ratio (LHR), which potentially reflects the oxygen metabolism and tissue perfusion, has not yet been sufficiently studied for IS prognosis prediction. To investigate the association between LHR and the 28-day all-cause mortality in patients with IS.
Methods: This MIMIC-IV database-based study included 866 patients with IS. Kaplan-Meier curves were used to compare survival between the log (LHR) subgroups. Multivariate Cox regression was performed with adjustment for the Glasgow Coma Scale (GCS) score, and robustness verification was further implemented by controlling for the SOFA score. An RCS analysis was used to explore the underlying nonlinear associations, followed by subgroup and mediation analyses.
Results: A survival analysis demonstrated a significantly higher 28-day mortality in log (LHR)≥ 2.32 than in the log (LHR) <2.32 groups (log-rank P = 0.017). In the Cox regression analysis with full adjustment for confounding factors, for every unit increase in log (LHR), the 28-day mortality risk increased by 38.1% (HR = 1.381, 95% CI: 1.111-1.718). The mortality risk of patients with log (LHR) ≥ 2.32 increased by 47.8% compared to those with log (LHR) <2.32 (HR = 1.478, 95% CI: 1.075-2.031). The RCS analysis showed no significant non-linear relationship between log (LHR) and the 28-day mortality rate (P-non-linear = 0.859). No significant interaction was observed in the subgroup analyses, and the relevant associations remained statistically significant within the severe stroke subgroup. After adjusting for the GCS and SOFA scores, the independent prognostic value of log (LHR) remained consistent. A mediation analysis showed that white blood cell count (mediation ratio, 33.54%) and blood urea nitrogen (mediation ratio, 18.69%) partially mediated the relationship between log (LHR) and mortality risk. The original LHR was also independently correlated with the mortality rate (HR = 1.018, 95% CI: 1.006-1.030).
Conclusions: LHR was positively correlated with 28-day mortality in patients with IS, independent of stroke severity, sepsis, and systemic organ failure, and inflammation, and renal dysfunction may jointly mediate this association. As an easily accessible composite indicator, LHR has potential clinical application value in early risk stratification.